The Phenotypic Spectrum of PNKP-Associated Disease and the Absence of Immunodeficiency and Cancer Predisposition in a Dutch Cohort.


Journal

Pediatric neurology
ISSN: 1873-5150
Titre abrégé: Pediatr Neurol
Pays: United States
ID NLM: 8508183

Informations de publication

Date de publication:
12 2020
Historique:
received: 05 05 2020
revised: 19 07 2020
accepted: 23 07 2020
pubmed: 28 9 2020
medline: 9 10 2021
entrez: 27 9 2020
Statut: ppublish

Résumé

We aimed to expand the number of currently known pathogenic PNKP mutations, to study the phenotypic spectrum, including radiological characteristics and genotype-phenotype correlations, and to assess whether immunodeficiency and increased cancer risk are part of the DNA repair disorder caused by mutations in the PNKP gene. We evaluated nine patients with PNKP mutations. A neurological history and examination was obtained. All patients had undergone neuroimaging and genetic testing as part of the prior diagnostic process. Laboratory measurements included potential biomarkers, and, in the context of a DNA repair disorder, we performed a detailed immunologic evaluation, including B cell repertoire analysis. We identified three new mutations in the PNKP gene and confirm the phenotypic spectrum of PNKP-associated disease, ranging from microcephaly, seizures, and developmental delay to ataxia with oculomotor apraxia type 4. Irrespective of the phenotype, alpha-fetoprotein is a biochemical marker and increases with age and progression of the disease. On neuroimaging, (progressive) cerebellar atrophy was a universal feature. No clinical signs of immunodeficiency were present, and immunologic assessment was unremarkable. One patient developed cancer, but this was attributed to a concurrent von Hippel-Lindau mutation. Immunodeficiency and cancer predisposition do not appear to be part of PNKP-associated disease, contrasting many other DNA repair disorders. Furthermore, our study illustrates that the previously described syndromes microcephaly, seizures, and developmental delay, and ataxia with oculomotor apraxia type 4, represent the extremes of an overlapping spectrum of disease. Cerebellar atrophy and elevated serum alpha-fetoprotein levels are early diagnostic findings across the entire phenotypical spectrum.

Sections du résumé

BACKGROUND
We aimed to expand the number of currently known pathogenic PNKP mutations, to study the phenotypic spectrum, including radiological characteristics and genotype-phenotype correlations, and to assess whether immunodeficiency and increased cancer risk are part of the DNA repair disorder caused by mutations in the PNKP gene.
METHODS
We evaluated nine patients with PNKP mutations. A neurological history and examination was obtained. All patients had undergone neuroimaging and genetic testing as part of the prior diagnostic process. Laboratory measurements included potential biomarkers, and, in the context of a DNA repair disorder, we performed a detailed immunologic evaluation, including B cell repertoire analysis.
RESULTS
We identified three new mutations in the PNKP gene and confirm the phenotypic spectrum of PNKP-associated disease, ranging from microcephaly, seizures, and developmental delay to ataxia with oculomotor apraxia type 4. Irrespective of the phenotype, alpha-fetoprotein is a biochemical marker and increases with age and progression of the disease. On neuroimaging, (progressive) cerebellar atrophy was a universal feature. No clinical signs of immunodeficiency were present, and immunologic assessment was unremarkable. One patient developed cancer, but this was attributed to a concurrent von Hippel-Lindau mutation.
CONCLUSIONS
Immunodeficiency and cancer predisposition do not appear to be part of PNKP-associated disease, contrasting many other DNA repair disorders. Furthermore, our study illustrates that the previously described syndromes microcephaly, seizures, and developmental delay, and ataxia with oculomotor apraxia type 4, represent the extremes of an overlapping spectrum of disease. Cerebellar atrophy and elevated serum alpha-fetoprotein levels are early diagnostic findings across the entire phenotypical spectrum.

Identifiants

pubmed: 32980744
pii: S0887-8994(20)30270-8
doi: 10.1016/j.pediatrneurol.2020.07.014
pii:
doi:

Substances chimiques

PNKP protein, human EC 2.7.1.-
Phosphotransferases (Alcohol Group Acceptor) EC 2.7.1.-
DNA Repair Enzymes EC 6.5.1.-

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

26-32

Informations de copyright

Copyright © 2020 The Author(s). Published by Elsevier Inc. All rights reserved.

Auteurs

Mark R Garrelfs (MR)

Department of Pediatrics, Radboud University Medical Center, Nijmegen, the Netherlands. Electronic address: m.r.garrelfs@amsterdamumc.nl.

Sanami Takada (S)

Laboratory for Immunology, Department of Pediatrics, Leiden University Medical Center, Leiden, the Netherlands.

Erik-Jan Kamsteeg (EJ)

Department of Human Genetics, Radboud University Medical Center, Nijmegen, the Netherlands.

Sjoert Pegge (S)

Department of Radiology, Radboud University Medical Center, Nijmegen, the Netherlands.

Grazia Mancini (G)

Department of Clinical Genetics, Erasmus University Medical Center, Rotterdam, the Netherlands.

Marc Engelen (M)

Department of Pediatric Neurology, Amsterdam University Medical Center, Amsterdam, the Netherlands.

Bart van de Warrenburg (B)

Department of Neurology, Donders Institute for Brain, Cognition, and Behaviour, Nijmegen, the Netherlands.

Alexander Rennings (A)

Department of Internal Medicine, Radboud University Medical Center, Nijmegen, the Netherlands.

Judith van Gaalen (J)

Department of Neurology, Donders Institute for Brain, Cognition, and Behaviour, Nijmegen, the Netherlands.

Ivo Peters (I)

Department of Neurology, Donders Institute for Brain, Cognition, and Behaviour, Nijmegen, the Netherlands.

Corry Weemaes (C)

Department of Pediatrics, Radboud University Medical Center, Nijmegen, the Netherlands.

Mirjam van der Burg (M)

Laboratory for Immunology, Department of Pediatrics, Leiden University Medical Center, Leiden, the Netherlands.

Michèl A Willemsen (MA)

Department of Pediatrics, Radboud University Medical Center, Nijmegen, the Netherlands; Department of Pediatric Neurology, Radboud University Medical Center, Amalia Children's Hospital and Donders Institute for Brain, Cognition and Behavior, Nijmegen, the Netherlands.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH